PRLD Prelude Therapeutics

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows:

Wells Fargo 18th Annual Healthcare Conference Boston
 Kris Vaddi, Ph.D., Chief Executive Officer will participate in a Fireside chat on Wednesday, September 6, at 4:30 p.m. ET. The live webcast is available . Dr. Vaddi and Laurent Chardonnet, Chief Financial Officer of Prelude, will host one-on-one meetings at the conference.



H. C. Wainwright 25th Annual Healthcare Investment Conference
 Dr. Vaddi and Jane Huang, MD, President and Chief Medical Officer will participate in a Fireside chat on Monday, September 11, at 1:30 p.m. ET. The live webcast is available . Dr. Vaddi, along with Dr. Huang and Mr. Chardonnet will host one-on-one investor meetings at the conference.



Morgan Stanley 21st Annual Global Healthcare Conference
 On Tuesday, September 12, at 4:55 p.m. ET, Dr. Vaddi and Dr. Huang will participate in a Fireside chat. The live webcast is available . Dr. Vaddi, Dr. Huang and Mr. Chardonnet will conduct one-on-one investor meetings at the conference.
  

About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best/first-in-class proprietary small molecule compounds aimed at addressing specific pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4/6 inhibitor, PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, and a preclinical oral candidate targeting SMARCA2.

For more information, visit our and follow us on and .

Investor Contact: 

Lindsey Trickett 

Vice President, Investor Relations 

240.543.7970 

Media Contact: 

Helen Shik

Shik Communications

617.510.4373



EN
29/08/2023

Underlying

PRLDPrelude Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Prelude Therapeutics

 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2025:On Thursday, June 5, 2025, at 3:10 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. Goldman Sachs 46th Annual Global Healthcare Conference:On Wednesday, June 11, 2025, at 9:20 a.m. ET, Kris, Vaddi, Ph.D., ...

June 2, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Reports First Quarter 2025 Financial Results and ...

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude’s once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with $103.1 million in cash, cash equivalents, restricted cash and marketable securities as of March 31...

May 6, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics to Participate in Citizens Life Sciences Conferen...

Prelude Therapeutics to Participate in Citizens Life Sciences Conference WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025. On Wednesday, May 7, 2025, at 11:00 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Peggy Scherle, Ph.D., Chief Scientific Officer will participate in a fireside chat. A live webcast of the ...

May 1, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Announces Presentations at 2025 AACR Annual Meeting

Prelude Announces Presentations at 2025 AACR Annual Meeting Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude’s efforts to discover and develop selective KAT6A degraders, including preclinical data, demonstrating potential for a differentiated efficacy and safety profile WILMINGTON, Del., April 25, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation o...

April 25, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
WWW Wolverine World...
ULTA ULTA BEAUTY INC ... (+60)

Monthly Insider Special Screens: April 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

WWW WOLVERINE WORLD WIDE INC.
ULTA ULTA BEAUTY INC
STAA STAAR SURGICAL CO.
SIGI SELECTIVE INSURANCE GROUP INC.
SIG SIGNET JEWELERS LIMITED
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
PSEC PROSPECT CAPITAL CORPORATION
PEB PEBBLEBROOK HOTEL TRUST
OSUR ORASURE TECHNOLOGIES INC.
OPK OPKO HEALTH INC.
OMCL OMNICELL INC.
MTDR MATADOR RESOURCES COMPANY
MEI METHODE ELECTRONICS INC.
JCOM J2 GLOBAL INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUN HUNTSMAN CORPORATION
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
HSC
I3N HARSCO CORPORATION
FSS CHART INDUSTRIES INC.
EVH FEDERAL SIGNAL CORPORATION
ECPG EVOLENT HEALTH INC CLASS A
CMC ENCORE CAPITAL GROUP INC.
APPS COMMERCIAL METALS COMPANY
AMRC DIGITAL TURBINE
ADBE AMERESCO
HRTG ADOBE INC.
FMC HERITAGE INSURANCE HOLDINGS INC.
MAC FMC CORPORATION
LIVE MACERICH COMPANY
FLGT LIVE VENTURES
FCNCA FULGENT GENETICS
DMLP FIRST CITIZENS BANCSHARES INC. CLASS A
RCII DORCHESTER MINERALS L.P.
FTDR RENT-A-CENTER INC
NFE FRONTDOOR INC.
GRWG NEW FORTRESS ENERGY
PCB GROWGENERATION
CMPR PACIFIC CITY FINANCIAL CORP
RC CIMPRESS PLC
ACA GRUPO RADIO CENTRO S.A.B. DE C.V.
RZLT ARCOSA
ONEW REZOLUTE
PRLD INC.
FET ONEWATER MARINE
IMNM PRELUDE THERAPEUTICS
CMTG FORUM ENERGY TECHNOLOGIES
LYEL IMMUNOME
BTMD CLAROS MORTGAGE TRUST
IE INC.
EBC LYELL IMMUNOPHARMA INC
MODD HAYMAKER ACQUISITION CORP III
MRNA IVANHOE ELECTRIC INC
FG EASTERN BANKSHARES INC
MODULAR MEDICAL INC
MODERNA
INC.
F AND G ANNUITIES AND LIFE
INC.
04/02/25 April 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch